Norwegian government-owned evergreen investment company providing risk capital to promising unlisted companies with international growth ambitions.
Auto-detected from Investinor's website.
20+ years venture investing in health and technology, focusing on new investments and portfolio follow-up in biotech, medtech, and digital health.
M.Sc. financial economics NTNU, MFin MIT, focuses on healthcare portfolio and bringing Norwegian medical technology to international markets.
Since 2014 manages state engagement in 14 seed funds with 4.3 billion NOK, invested in over 200 companies since 2008.
M.Sc. Finance NHH, worked with software and deep tech companies since 2015, combines capital management with active ownership.
Former Head of Venture at NTNU TTO, focuses on software and healthcare companies with active value-creating ownership.
15 years fund investing at Innovasjon Norge, MBA University of Bath, focuses on venture fund investments.
Cand.merc. NHH and Universität St.Gallen, focuses on technology companies in energy sector since 2013.
Master Technology Management NTNU/MIT Sloan, former investment director at Innovasjon Norge, focuses on venture fund investments.
25 years CEO-level experience at Siemens, focuses on scale-up phase companies in digitalization, semiconductor, and deep tech.
Since 2011 led 150+ transactions across sectors, managed seed portfolio and venture funds, contributed to 10+ successful exits.
Fund manager for Investinor Direkte 4, specializes in deep tech and healthcare growth equity investments since 2017.
20+ years investment and transaction experience, partner in venture funds, investment banker, cand.jur University of Oslo.
Responsible for pre-seed investments and co-investment fund for North Norway, former investment director at Innovasjon Norge.
Since 2009 focuses on technology and aquaculture companies, former CFO Norway Royal Salmon, financial analyst covering Oslo Børs.
With Investinor since establishment, former CFO, finds and follows unlisted growth companies with international ambitions.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.